Can AI Make Better Drugs? Not on Wall Street’s Timeline

The technology has arrived in the drug lab. But should investors pay up for it? investment News Pharmaceuticals,Healthcare/Life Sciences,Manufacturing,Artificial Intelligence/Machine Learning,Cancer,Political/General News,Computer Science,Health,Medical Conditions (Discontinued from 14th July 2026),Sciences/Humanities,Content Types,Columns,SYND,WSJ-PRO-WSJ.com,GCAPI,Eli Lilly,LLY,Novartis,NOVN.EB,CH:NOVN,Eli Lilly’s,Novartis’s,LINK:EN|drn:realtime.linkedarticle.DNCO20260712000037,LINK|i1-WP-WSJ-0003725637,LINK|i2-WP-WSJ-0003725637,artificial intelligence,machine learning,political,general news,sciences,humanities,healthcare,life sciences